Related Experiment Video

Updated: May 5, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Mycophenolate mofetil therapy in children with idiopathic membranous nephropathy

Rajendra Bhimma1, Elaene Naicker, Pratistadevi K Ramdial

  • 1Department of Pediatrics, Department of Anatomical Pathology, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, KwaZulu-Natal, and National Health Laboratory Service, South Africa.

Clinical Nephrology
|November 23, 2013
PubMed
Abstract

Insights

Mycophenolate mofetil (MMF) shows promise in treating childhood idiopathic membranous nephropathy (IMN). This immunosuppressive therapy, combined with steroids, reduced proteinuria in most young patients with minimal side effects.

Area of Science:

  • Pediatric Nephrology
  • Immunosuppressive Therapy
  • Rare Diseases

Background:

  • Idiopathic membranous nephropathy (IMN) is a rare kidney disease affecting children.
  • Current management protocols for pediatric IMN are not standardized.
  • This study investigates the use of mycophenolate mofetil (MMF) in pediatric IMN cases.

Purpose of the Study:

  • To evaluate the safety and efficacy of mycophenolate mofetil (MMF) in children with idiopathic membranous nephropathy (IMN).
  • To report outcomes of MMF treatment in a small cohort of pediatric patients.

Main Methods:

  • Four children with histopathologically confirmed Stage III IMN were treated.
  • Treatment involved MMF (1,200 mg/m2/day) combined with low-dose steroids and ACE inhibitors.
  • The minimum treatment duration was six months.

Main Results:

  • Three out of four children achieved over 50% reduction in proteinuria, maintaining renal function.
  • One patient did not respond and progressed to Stage III chronic kidney disease.
  • No major adverse side effects were observed in children treated with MMF.

Conclusions:

  • MMF is a safe and effective immunosuppressive agent for pediatric IMN when used short-term with steroids and ACE inhibitors.
  • Further large-scale, multicenter randomized trials are needed to confirm MMF's efficacy and long-term safety in children with IMN.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.1K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
108
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
422